Volasertib is under clinical development by Oncoheroes Biosciences and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Volasertib’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 27 Jun 2022 decreased Volasertib’s Phase Transition Success Rate (PTSR) for Solid Tumor.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Volasertib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Volasertib overview

Volasertib (BI 6727) is under development for the treatment of myelodysplastic syndrome, rhabdomyosarcoma, acute myeloid leukemia (AML) and solid tumors including leukemia, lymphoma. The drug candidate is administered as intravenous infusion. The drug targets polo-like kinase 1 (PLK-1). It is a new chemical entity (NCE).

It was also under development for the treatment of refractory anemia with excess blasts, chronic myelomonocytic leukemia (CMML), metastatic urothelial cancer, acute myeloid leukemia, ovarian cancer, non-small cell lung cancer, acute lymphoblastic leukemia, relapsed and refractory cutaneous T-cell lymphoma, peripheral T-cell lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma and burkitt lymphoma.

Oncoheroes Biosciences overview

Oncoheroes Biosciences is a biotechnology company which discovers, develops and commercializes oncology drugs for the treatment of childhood and adolescent cancers. The company is investigating 2HIT, a drug used for the treatment of central nervous system malignant tumor and volasertib, a polo like kinase 1 (PLK1) inhibitor targeting rhabdomyosarcoma (RMS), a pediatric soft tissue sarcoma. It works in partnership with Xenopat, CDTI, Institute for bioengineering of California and other companies to develop its products. Oncoheroes Biosciences is headquartered in Brookline, Massachusetts, the US.

Quick View Volasertib LOA Data

Report Segments
  • Innovator
Drug Name
  • Volasertib
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.